BioAmber Inc.
1250, Rene-Levesque Boulevard West
Suite 4110
Montreal
Quebec
H3B 4W8
Canada
Tel: 514-844-8000
Fax: 514-844-1414
Website: http://www.bio-amber.com/
91 articles about BioAmber Inc.
-
BioAmber Provides Update on Liquidation Process Under the Companies Creditors' Arrangement Act, R.S.C. 1985, c. C-36
10/25/2018
PricewaterhouseCoopers Inc., LIT, in its capacity as the court-appointed Monitor (in such capacity, the "Monitor") of BioAmber Inc. (OTCPK: BIOAQ), BioAmber Canada Inc., and BioAmber Sarnia Inc. (collectively, the "Company") in their proceedings under the Companies Creditors' Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA"), provides the following update on the Company's liquidation process.
-
BioAmber Provides Update on Liquidation Process & Announces Resignations of Board Members and Officers
8/31/2018
BioAmber Inc. announces that following a Court order issued on August 28th, 2018, the stay period ordered by the Court in connection with its restructuring process under the terms of the Companies' Creditors Arrangement Act has been extended until September 18th, 201
-
BioAmber Provides Update on Liquidation Process
8/9/2018
BioAmber Inc. has initiated a liquidation process pursuant to which offers will be solicited from liquidators and/or strategic buyers to proceed with the liquidation of the company's assets or a recapitalization transaction with the goal of realizing the greatest value on behalf of the company's creditors.
-
BioAmber Provides Update on Sales Process
7/30/2018
BioAmber Inc. (OTCPK: BIOAQ) announces that the current stage of the Sales and Investor Solicitation Process (SISP) has concluded without an acceptable offer having been received from a Qualified Bidder as of the due date of July 27, 2018.
-
BioAmber's Special Meeting of Stockholders Suspended and Update on Restructuration Process
6/7/2018
BioAmber Inc. has been suspended by the Superior Court of the Province of Quebec
-
BioAmber Inc. Announces Record Revenues for the Fourth Quarter and Year End 2017
3/27/2018
BioAmber Inc. announced operational and financial results for the three months and year ended December 31, 2017.
-
BioAmber Delays Filing of Annual Report on Form 10-K and Postpones Earnings Release and Conference Call for Fourth Quarter and Full Year 2017
3/15/2018
BioAmber Inc. announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission (the "SEC") regarding a delay in the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
-
BioAmber Receives Notice of Delisting by TSX
2/16/2018
These measures were taken due to the Company not meeting the continued listing requirements of the TSX.
-
BioAmber Receives Notice of Delisting Review by TSX
2/14/2018
This review results from the Company not being in a position to obtain the approval of the TSX in connection with its registered direct offering announced on February 9, 2018.
-
BioAmber Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering
2/9/2018
The Series A warrants have an exercise price of US$0.15 and a term of six months, exercisable upon the date of issuance.
-
BioAmber Announces Underwritten Offering
2/6/2018
The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
-
BioAmber Announces Pricing of $10M Underwritten Public Offering
2/6/2018
The Series A warrants have an exercise price of US$0.25 and a term of six months, exercisable upon the date of issuance.
-
BioAmber Restructures its Credit Facility With its Senior Lenders
1/26/2018
This amendment to the loan agreement removes certain financial covenants under the terms of the loan agreement with the senior lenders, namely a minimum cash requirement and ongoing revenue covenants.
-
BioAmber Announces Third Quarter 2017 Financial Results
11/8/2017
Sales of bio-succinic acid were $3.3M, compared to $3.7M in Q3 2016.
-
BioAmber Announces Webcast of Fiscal Third Quarter 2017 Financial Results
10/27/2017
BioAmber today announced that it will report financial results for the third quarter 2017 on Tuesday, November 7, 2017 after markets close.
-
BioAmber President and COO Steps Down
10/25/2017
BioAmber announced today that it has accepted the resignation of Mr. Fabrice Orecchioni as President and COO.
-
BioAmber Receives Notice Of Non-Compliance From The NYSE
9/14/2017
-
BioAmber Announces New Chief Executive Officer
9/14/2017
-
BioAmber Announces US$11 Million Underwritten Offering Of Common Stock And Warrants
8/8/2017
-
BioAmber Announces Underwritten Offering Of Common Stock And Warrants
8/8/2017